
Suven Life Sciences Q2 FY20 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Commercial CRAMS revenue is expected to be around Rs.180-190 crore for the current year, with a possibility of reaching up to Rs.190 crore, though Q2 numbers may not repeat consistently.
- Specialty Chemicals revenue is anticipated to grow modestly from Rs.210 crore to approximately Rs.220-230 crore in the full year, with a 5-10% growth range.
- Regular CRAMS may grow at about 10-20% over the next six months and FY’21, subject to customer success and normal business conditions.
- Two more specialty chemical molecules are in early development, expected to become commercial around FY’21 or FY’22.
- Overall CAPEX is Rs.130-140 crore in the current year and Rs.100-120 crore next year, supporting growth.
- Some fluctuation in quarterly revenue is expected due to lumpiness in order timing and product launches.
- Future growth is cautiously optimistic but dependent on client approvals and clinical trial success of key molecules.
See what Suven Life Sciences management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Suven Life Sciences management said on order book — free account, 30 seconds.
Capex plans
Yes- Total CAPEX planned around Rs. 130-140 crore this year, approximately Rs. 100 crore in the current financial year and Rs. 50 crore in the next year. (Page 12, Page 8)
- Out of Rs. 320 crore overall CAPEX, Rs. 160 crore is to be spent soon; Rs. 100 crore already spent on Pashamylaram facility, to be capitalized by Q3; facilities in Vizag and formulations expected to be ready by end of next year's Q3. (Page 10)
- Additional maintenance CAPEX around Rs. 30-40 crore separate from new CAPEX. (Page 11)
- Rs. 150 crore pending CAPEX is planned, with investment ongoing in occupational exposure level facility in Pashamylaram, to be commercialized soon. (Page 6)
- CAPEX expected to support capacity expansion for CRAMS and generic business growth, but only six months visibility currently available. (Page 6)
- No major CAPEX anticipated for Rising Pharma as it is a development and distribution company without major asset base. (Page 14)
Track Suven Life Sciences — get its next earnings analysis in your feed
How does Suven Life Sciences rank vs peers in Healthcare Services?
Pro featureHow does Suven Life Sciences rank in Healthcare Services?
Compare Suven Life Sciences against every Healthcare Services company (Q2 FY20) on revenue, margins and earnings-call signals.
Continue your research
What Suven Life Sciences's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.